LLY vs AMGN
By Alex · Tickerpine
Eli Lilly and Company vs Amgen Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | LLY | AMGN |
|---|---|---|
| Price | $1,443.50 | $465.67 |
| Market cap | $1.29T | $251.89B |
| P/E ratio | 46.9 | 27.0 |
| ROE | 86.02% | 78.35% |
| Profit margin | 31.90% | 24.14% |
| Revenue growth | 38.60% | 8.50% |
| Dividend yield | 0.48% | 2.16% |
| Beta | 0.39 | 0.42 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
LLY vs AMGN in plain English
- LLY is the bigger company — about 5.1× the market cap of AMGN.
- AMGN is cheaper on earnings (P/E 27.0 vs 46.9).
- LLY earns a higher return on equity (86% vs 78%).
- LLY is growing revenue faster (39% vs 8%).
- AMGN has the higher dividend yield (2.16% vs 0.48%).
How would $1,000 have done in each?
LLY return calculator
See what $1,000 in Eli Lilly and Company would be worth today.
AMGN return calculator
See what $1,000 in Amgen Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.